Speichinger Fiona, Berg Ann-Kathrin, Stoyanova Ani, Lauscher Johannes Christian, Kamphues Carsten, Beyer Katharina, Seifarth Claudia, Slavova Nadia, Schineis Christian
Department of General and Visceral Surgery, Charité Universitätsmedizin Berlin, 12203 Berlin, Germany.
Department of General and Visceral Surgery, Park-Klinik Weißensee Berlin, 13086 Berlin, Germany.
J Clin Med. 2024 Jun 18;13(12):3568. doi: 10.3390/jcm13123568.
: The COVID-19 pandemic and its associated restrictions have resulted in delayed diagnoses across various tumor entities, including rectal cancer. Our hypothesis was based on the expectation of a reduced number of primary operations due to higher tumor stages compared to the control group. : In a single-center retrospective study conducted from 1 March 2018 to 1 March 2022, we analyzed 120 patients with an initial diagnosis of rectal cancer. Among them, 65 patients were part of the control group (pre-COVID-19), while 55 patients were included in the study group (during the COVID-19 pandemic). We compared tumor stages, treatment methods, and complications, presenting data as absolute numbers or mean values. : Fewer primary tumor resections during the COVID-19 pandemic ( = 0.010), as well as a significantly lower overall number of tumor resections ( = 0.025) were seen compared to the control group. Twenty percent of patients in the COVID-19 group received their diagnosis during lockdown periods. These patients presented significantly higher tumor stages (T4b: 27.3% vs. 6.2%, = 0.025) compared to the control group prior to the pandemic. In addition, more patients with angiolymphatic invasion (ALI) were identified in the COVID-19 group following neoadjuvant treatment compared to the control group ( = 0.027). No differences were noted between the groups regarding complications, stoma placement, or conversion rates. : The COVID-19 pandemic, particularly during lockdown, appears to have contributed to delayed diagnoses, resulting in higher tumor stages and a decreased number of surgeries. The quality of rectal cancer treatment can be maintained under pandemic conditions.
2019年冠状病毒病（COVID-19）大流行及其相关限制措施导致包括直肠癌在内的各种肿瘤实体的诊断延迟。我们的假设基于这样的预期：与对照组相比，由于肿瘤分期较高，初次手术的数量会减少。：在一项于2018年3月1日至2022年3月1日进行的单中心回顾性研究中，我们分析了120例初诊为直肠癌的患者。其中，65例患者为对照组（COVID-19之前），而55例患者纳入研究组（COVID-19大流行期间）。我们比较了肿瘤分期、治疗方法和并发症，以绝对数或平均值形式呈现数据。：与对照组相比，COVID-19大流行期间的原发性肿瘤切除术较少（ = 0.010），肿瘤切除术的总数也显著较低（ = 0.025）。COVID-19组中有20%的患者在封锁期间确诊。与大流行前的对照组相比，这些患者的肿瘤分期显著更高（T4b：27.3%对6.2%， = 0.025）。此外，与对照组相比，COVID-19组在新辅助治疗后发现更多有血管淋巴管侵犯（ALI）的患者（ = 0.027）。两组在并发症、造口放置或转化率方面未发现差异。：COVID-19大流行，尤其是在封锁期间，似乎导致了诊断延迟，从而导致肿瘤分期更高和手术数量减少。在大流行条件下可以维持直肠癌治疗的质量。
